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antidepressants to their patients? A pilot study
Alain Mercier1,6*, Isabelle Auger-Aubin2, Jean-Pierre Lebeau3, Matthieu Schuers1, Pascal Boulet1,
Paul Van Royen4 and Lieve Peremans4,5Abstract
Background: The frequency of antidepressant (ADs) prescription is high, with general practitioners (GPs)
responsible for about 80% of the prescriptions. Some studies considered prescriptions meet DSM criteria, while
others stress inadequate use. The importance of biological and psychosocial determinants of GP prescription
behaviour remains little explored. We aimed to describe the importance of these biological and psychosocial
determinants and their weight in the daily practice of GPs’.
Methods: During a week chosen at random, 28 GPs collected the AD prescriptions made within the previous six
months, regardless of the reason for the patient contact. Bio psychosocial and AD treatment characteristics were
recorded for all patients. In a random sample of 50 patients, patient characteristics were assessed via a structured
face-to-face interview with the GP.
Results: The frequency of AD prescription was 8.90% [3.94 -17.02]. The GPs initiated 65.6% [60.1-70.8] of the
prescriptions. The rate of AD prescription for non-psychiatric conditions was 18%. Patients had from 1 to 9 conditions,
showing a high level of multi-morbidity. There was a strong influence of past medical history and contextual problems,
such as work related problems.
Conclusion: AD prescription is related to complex contextual situations and multi-morbid patients. GPs use a
bio psycho social approach, rather than a purely biological assessment. Awareness of these influences could improve
prescription by GPs.
Keywords: Antidepressants, Primary care, General practitioner, Prescription, Off label useBackground
Antidepressant (AD) sales increased sevenfold in indus-
trialized countries from 1980 to 2008 and have remained
rather stable since then [1-3]. In the overall population,
the 12-month rate of AD consumption ranges from 6%
to nearly 10% [3-5]. The AD consumption is very high
in France (9.7%) and in the USA (10.7%) [6-8]. In all
countries, General Practitioners (GPs) are responsible
for about 80% of these prescriptions [2,9]. This high
level of consumption could be explained by a greater de-
mand for medical care and an increased number of pa-
tients treated for depression [10,11]. The increasing rate* Correspondence: alain.mercier@univ-rouen.fr
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unless otherwise stated.of long-term treatment of depressed people could also
explain this consumption [12]. ADs are also prescribed
for other mental disorders, such as anxiety [13] and for
minor depression [3,14]. ADs could also be adequately
used in treating non-psychiatric conditions such as pain
[15]. Some studies have shown that most patients (86-
95%) diagnosed as depressed and treated by their GP
with ADs met the DSM-IV depression criteria of a major
depressive disorder (MDD) [16,17]. Others showed that
the rate of off-label prescriptions varies between 20%
and 60% of all prescribed ADs [18,19]. They are also
prescribed in an inadequate manner, such as a too short
duration of treatment [20] or in a sub-therapeutic dos-
age [3]. All these discrepancies suggest a lack of data,
probably related to the complex real-life situations seen
in primary care: Qualitative research has revealed that
GPs usually prescribe ADs for non-psychiatric or mixedLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tient characteristics [21,22]. The relative influence of
these factors on AD prescription among GPs remains
unexplored, particularly regarding the characteristics of
the patients’ condition and their social environment. The
main aim of this pilot study is to more precisely describe
the importance of these biological and psychosocial de-
terminants as they relate to GPs in their daily practice.
Methods
AD prescriptions and the characteristics of patients who
had been prescribed an AD in the last six months were
gathered.
Pilot study participants and settings
The study was conducted in the Normandy region of
France, in the northwestern area of the country. Like
many regions, it includes industrialized cities (e.g. Rouen,
Le Havre) as well as rural areas and has an overall popula-
tion of 1.9 million inhabitants. Access to the health care
system does not differ from the usual standard of the
country: In France, GPs are the first medical contact for
the patients and provide open access to its users, dealing
with all health problems regardless of the age, sex, or any
other characteristic of the person concerned. A three
year specialized curriculum, (or official equivalency) is
mandatory to practice as a GP. All GPs from our local
research network were invited to participate in the
study. Those invited all worked full-time at a primary am-
bulatory care practice, only seeing outpatients. None of
the physicians worked in specialized or secondary care set-
tings (e.g. hospital, clinics).
Data collection
The GPs collected the data during a week chosen at ran-
dom between December 2011 and March 2012. We in-
cluded all patients who had been prescribed an AD
within the previous six months, including renewals and
new prescriptions, regardless of the reason for contact,
and whether or not this prescription was continued later
on. Patient characteristics (gender, age, socio-professional
category and marital status) and the AD treatment charac-
teristics (dosage, estimated starting date, and initiator of
the prescription) were recorded. In order to focus in depth
on all biological and psychosocial characteristics, we ran-
domly selected from each GP two patients who had been
prescribed an AD within the previous six months. The se-
lection was stopped when a total of 50 patient files had
been drawn. Once these files were selected, the patients’
characteristics were assessed via a structured face-to-face
interview with the GP. The assessment included risk fac-
tors for depression and on-label and off-label conditions
for AD prescription. All other characteristics encountered
during our previous qualitative analysis of AD prescriptionby GPs’ were also collected [22]. Those characteristics
were related to the psycho-social context of the patient
(e.g. relational conflicts in the family, social loneliness, see
Table 1), past history, and on-going conditions, as they
were perceived by the GPs. During the interview, the GPs
were asked to use information from the patient’s file and
to rate the influence of each characteristic for each AD
prescription (“0” for no influence on their AD prescrip-
tion, “1” for a slight influence and “2” for a major influ-
ence). The aim was to weight the relative influence of the
factors for an AD prescription according to the GP him-
self. We wanted to point out the influence of less preva-
lent factors than psychiatric disorders (e.g. life events, pain
conditions).
Objectives and outcomes
We wanted first to determine the number of AD prescrip-
tions by the GPs, the characteristics of these prescriptions
both for psychiatric and non-psychiatric conditions (name
of AD, dosage and duration of treatment), and the bio-
logical and psychosocial characteristics of the patients, in-
cluding the patients’ socio-professional category. Three
categories - on-going problems, patient history, and bio-
medical conditions - were distinguished. Secondly, we
assessed the influence of these determinants based on the
interviews with the prescribing GPs.
Based on data regarding prescription of ADs for non-
psychiatric conditions, our initial hypothesis was that a 20%
prevalence of AD prescriptions not related to any psychiatric
condition would be found [3,18]. The other hypothesis was
that the GPs’ decision would be influenced by multiple fac-
tors related to the complexity of general practice situations.
Analysis
Data were collected using Excel®. Any outlier and missing
data were tracked. A descriptive analysis was performed
using “epi-info® 3.53”. To get an indication of the weight of
the influencing factors for the 50 randomly chosen pa-
tients, the sum of all individual determinant scores, rated
from 0 to 2 for each patient, was calculated. The mean
number and range of influencing factors per patient as well
as the modus score for each influencing factor was deter-
mined. We determined the strength of influence by divid-
ing the score of influence by the prevalence for each factor.
Ethical aspects
The local ethics committee (CPP Nord-Ouest) stated
that an authorization was not required for this non-
interventional study.
Results
GP characteristics
Among the 56 GPs invited, 28 (6 females and 22 males)
agreed to participate. The mean age was 48.5 years (32–63;
Table 1 Diagnosis, psychosocial context, past history, and ongoing conditions (n = 50)
All patients
n = 50
All patients with at
least one psychiatric
diagnosis(1) n = 41
All patients with
a depressive
episode(2) n = 31
All patients with a
major depressive
episode (intense)(3)
n = 20
All patients with
no psychiatric
diagnosis n = 9
Gender Female 34 29 21 13 5
Age Mean/Range 52.8 [19–91] 50.6 [19–91] 48.8 [19–91] 45.8 [19–77] 62 [40–84]
Job Professional activity 26 22 17 11 3
Socio- professional
class
Low income 19 17 11 7 2
Intermediate to high income/ 15 12 11 9 3
retirement 16 12 9 4 4
Marital status Living together/Married 21 15 17 4 8
Single, Divorced, separation 19 17 15 12 0
Widowed 10 9 9 4 1
Relational conflicts in family 18 17 15 11 1
Current context Disability (official status) 8 6 5 3 2
Social loneliness/Socially
isolated patient
5 5 5 5 0
Work-related problems 17 14 10 5 3
Legal problems/Current
legal situation
4 4 4 4 0
Recent bereavement/Recent
death in the entourage
12 9 9 5 3
Position of family care giver 7 7 5 3 0
Patient physically or
psychologically dependent
7 7 6 4 0
Facing discrimination 5 5 4 2 0
Current tobacco
consumption
14 12 10 6 2
Excessive alcohol
consumption
3 3 2 2 0
Other addictions (Opiates,
gambling, etc.)
6 5 4 3 1
Substitution therapy
(methadone, buprenorphine)
1 1 1 1 0
Number of contextual factors by patient Mean/Range 2.1 [0–6] 2.31 [0–6] 2.7 [0–6] 2.6 [0–6] 1.33 [0–4]
Past history of
patient
Past history of suicide attempt 6 6 4 3 0
Tobacco consumption 18 15 12 8 3
Past history of excessive
alcohol consumption
7 6 5 5 1
Other addictions
(e.g. opiates, gambling)
4 3 4 3 1
Past history of depression
(different from current
episode)
19 18 14 8 1
Past history: Hospitalised in
psychiatric service, whatever
the reason
5 5 3 2 0
Family with psychiatric
conditions
10 9 5 5 1
Past history of AD prescription 23 22 15 9 1
Child abuse 5 4 3 3 1
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Table 1 Diagnosis, psychosocial context, past history, and ongoing conditions (n = 50) (Continued)
Number of past history factors by patient 2.1 [0–6] 2.1 [0–6] 2.3 [0–6] 2.0 [0–9] 1 [0–3]
Ongoing, non-psychiatric
conditions
Isolated sleeping problems 6 2 0 0 4
Dementia 2 1 0 0 1
Specific neuropathic pain 3 1 1 1 2
Sciatic pain 3 3 2 2 0
Migraine 3 2 1 0 1
Fibromyalgia 3 1 1 1 2
Musculo-skeletal complaints
or pain
16 14 13 7 2
Tension type headaches 7 7 4 3 0
Isolated fatigue 10 9 7 3 1
Functional gastro-intestinal
complaints: Irritable bowel
syndrome
12 9 6 0 3
Sexual dysfunction,
premature ejaculation
5 4 3 3 1
Enuresis, incontinence 3 3 3 2 0
Other chronic disease
(e.g. Diabetes type 2)
35 25 19 11 7
Chronic low back pain 6 5 2 2 1
Number of non-psychiatric conditions by patient
Mean/Range 2.28 [0–7] 2.09 [0–7] 1.75 [0–6] 2.0 [0–7] 2.77 [1-5]
Ongoing non-psychiatric
reasons
Chronic diffuse complaints 12 12 10 6 0
Unexplained complaints 13 11 8 3 2
Diffused pain 8 7 4 2 1
All reasons and conditions by patient Mean/Range 4.1 [1-9] 4.2 [1-9] 3.9 [1-9] 4.22 [1-9] 3.2 [1-5]
1All psychiatric conditions, including symptoms of depression without all criteria for a major episode, all diagnoses of anxiety.
2All depressive episodes, whatever the intensity.
3Major depressive episodes only.
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mentoring students. The mean duration of practice
was 17.8 years (3–35; SD = 10.5). The mean number of
patients met during the week of the study was 126
(56–260; SD = 40.4).
Overall patient characteristics
During the study week, the GPs saw 3,522 patients, 317
of whom (8.90%; [3.94 -17.02]) were prescribed an AD.
Two hundred twenty-nine patients were female (72.2%
[67–77.1]) and 88 (27.8% [23–33.1]) male. Their mean
age was 54 [18–91]. Fifty-six per cent (n = 178) were
married or living together; the others were single (n = 50
[16%]), divorced (n = 48 [15%]) or widowed (n = 41 [13%].
Most patients belonged to a low-income social class
(n = 68 [52%]). Overall, 235 patients (74.1% [68.9-78.9])
were prescribed “new” ADs (SSRIs and SNRIs). For more
than one in four patients, the AD treatment was initiated
during the previous six months (n = 83 [26%]). The par-
ticipating GPs themselves initiated 208 prescriptions (65.6
[60.1-70.8]). During the study week every GP had nearlythree patients (2.96) for whom they initiated an AD
prescription.
In-depth assessment of the 50-patient sample
The results are described in Table 1. Half of the patients
had no professional activity and 17 had work-related
problems. Nine patients had no diagnosis of any psychi-
atric condition. According to their GP, the other 41 had
a psychiatric diagnosis: major depressive episode, de-
pressive episode or anxiety, or sometimes a combination.
On the whole, patients had from 1 to 9 reasons or con-
ditions, (mean = 4.1) and from 0 to 8 non-psychiatric
conditions (mean = 2.94), showing a high level of multi-
morbidity. Many of these conditions were related to
pain.
The prevalence of the conditions assessed and their
most frequent influence score are shown in Table 2. The
relative influence for the most important of them is shown
in Table 3. Among the contextual factors, work-related
problems and recent bereavement showed both a high
prevalence and strong influence on AD prescription.
Table 2 Influence, prevalence, and modus of influence of each factor (n = 50)
Type of situation Condition or characteristic Total score of
Influence(1) (n)
Prevalence(2) (n) Most frequent influence
score(3) (modus)
Psychiatric conditions Anxiety (all) 41 24 2
Major depressive episode (intense) 40 20 2
Depressive episode (mild) 20 11 2
Symptoms of bad mood without
depression
4 3 1
Psychiatric-related
past history
Past history of AD prescription 30 23 2
Past history of depression 24 19 1/2
Family with psychiatric conditions 8 10 1
Past history of suicide attempt 7 7 1
Past history of excessive alcohol
consumption
4 6 0
Past history: Hospitalised in psychiatric
ward
4 5 1
Non-psychiatric
conditions
Other chronic disease (e.g.: Diabetes
type 2)
22 35 0
Musculo- skeletal complaints or pain 11 16 0
Isolated fatigue 11 10 2
Isolated sleeping problems 7 6 0/1
Functional gastro-intestinal complaints:
Irritable bowel syndrome
5 12 0
Sexual dysfunction, premature ejaculation 5 5 0/2
Specific neuropathic pain 5 3 2
Tension type headaches 4 7 0
Fibromyalgia 4 3 2
Chronic low back pain 3 6 0
Migraine 2 3 0
Dementia 2 2 0/2
Sciatica pain 1 3 0
Enuresis, incontinence 0 3 0
Non- psychiatric
reasons
Chronic complaints 13 12 1
Unexplained complaints 10 13 1
Diffused pain 10 8 2
Non- psychiatric past
history
Past history of mistreatment/child abuse 5 5 1
Past history of tobacco consumption 2 18 0
Past history of other addictions (e.g. Gambling) 1 5 0
Other factors Work-related problems 23 17 2
Recent bereavement/Recent death in
entourage
15 12 2
Legal problems/Current legal situation 8 4 2
Position of family care giver 7 7 1
Physically or psychologically dependent patient 6 7 0
Facing discrimination 6 5 1
Social loneliness/Socially isolated patient 6 5 1
Disability (official status) 5 8 0
Current tobacco consumption 2 14 0
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Table 2 Influence, prevalence, and modus of influence of each factor (n = 50) (Continued)
Other addictions (Opiates, gambling, etc.) 2 6 0
Excessive alcohol consumption 2 3 0
Replacement therapy (methadone,
buprenorphine)
0 1 0
(1)Total score is the sum of all individual influence scores (2 = Strong influence, 1 = possible influence, 0 = no influence) given for each condition/patient.
(2)Total prevalence may be > 50 as patients may have multiple conditions.
(3)Influence score most frequently given by the GPs. In the event of a tie, the two scores are separated by a slash (“/”).
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and depression were noticeably prevalent. Fibromyalgia and
neuropathic pain, though not so prevalent, nonetheless had
a strong influence on the decision to prescribe an AD.
Among the nine patients without a psychiatric disease, the
conditions often associated were fibromyalgia (n = 2), pain
(n = 2), premature ejaculation (n = 1), sleeping troubles
(n = 3, 2 for a withdrawal process), exhausted family care-
giver (n = 1) serious grief (n = 1). Other chronic diseases
for which an AD was prescribed included disability after a
stroke and chronic cardiac failure.
Discussion
Prescription of ADs: characteristics
This study confirmed the high frequency of AD pre-
scription in general practice. Nevertheless, one third ofTable 3 Strength of influence for the main factors
Condition or characteristic Influence score (*)
Major depressive episode (intense) 2
Legal problems/Current legal situation 2
Depressive episode (mild) 1.8
Anxiety (all) 1.7
Specific neuropathic pain 1.6
Work-related problems 1.3
Symptoms of bad mood without depression 1.3
Past history of AD prescription 1.3
Past history of depression 1.3
Fibromyalgia 1.3
Recent bereavement/Recent death in entourage 1.2
Facing discrimination 1.2
Social loneliness/Socially isolated patient 1.2
Diffused pain 1.2
Isolated fatigue 1.1
Isolated sleeping problems 1.1
Sexual dysfunction, premature ejaculation 1
Past history of suicide attempt 1
Dementia 1
Past history of mistreatment/child abuse 1
Position of family care giver 1
(*) The influence was determined by dividing the score of influence by the
prevalence for each factor.the AD prescriptions were not initiated by the GPs, but
were renewals. The rate of AD prescription varied con-
siderably, from 4% to 17% per GP, as has been observed
in other studies [23]. One patient in four (26%) had re-
cently been prescribed an AD, initiated by his own GP.
During the study week, each of the GPs saw an average
of 11 patients taking ADs: On average eight of the pa-
tients were already taking the AD and the physician ini-
tiated the prescription for the other three. One patient
in two had had a long-term prescription, more than one
year, which is consistent with other studies [10,12].Patient characteristics
The most prevalent and influential conditions were anx-
iety and depression, in contradiction with other studies
[6,18]. According to their GP, 76% of the patients pre-
sented with a full psychiatric condition. Women were
particularly affected. Only 6% of the patients presented
isolated psychological symptoms, and 18% no psychiatric
condition at all. The fact that anxiety was an important
reason for AD prescription must be highlighted, though
anxiety is partly associated with depression. French
health authorities have stigmatised the prescription of
benzodiazepines by GPs and their level of prescription
has stagnated [3], which has probably produced a shift
away from benzodiazepines towards more AD prescrip-
tions. The influence of a past history of depression or
previous AD prescription has also to be pointed out, as
it was already suggested from our previous qualitative
study [22]. Current use and past history of tobacco con-
sumption were highly common, a phenomenon previ-
ously known among these categories of patients [24].The importance of psychosocial situations
In addition to already known risk factors for depression
and psychiatric problems, the GPs underlined the influ-
ences of psychosocial factors. They reported that work
related problems had an important influence on their
decision. Legal problems, recent grief, and discrimin-
ation or social isolation also strongly influenced the GPs’
decisions. This study also confirmed previously known
factors for psychological and social distress: More than
half of the patients were single, divorced or widowed,
and belonged to a low-income social class.
Mercier et al. BioPsychoSocial Medicine 2014, 8:17 Page 7 of 9
http://www.bpsmedicine.com/content/8/1/17The importance of non-psychiatric conditions
For almost 20% of the enrolled patients, the reason for
an AD prescription was a non-psychiatric condition.
Many of the patients suffered from numerous on-going
conditions. These conditions were also present as well in
the case of psychiatric diseases as a co-morbid condition.
The GPs decided to prescribe ADs for chronic non-
psychiatric conditions such as chronic complaints, pain,
or sleep-related problems. Many of these non-psychiatric
conditions (pain, migraine, fibromyalgia migraine, and
premature ejaculation) met the criteria for scientific evi-
dence for the prescription of ADs [15,25-28]. This level of
evidence was lacking for some other conditions that influ-
enced GPs, e.g. isolated sleep related problems or sciatica
and low back pain, but these conditions were not the sole
reason for prescription to these patients. They also had
chronic ischemic artery conditions and type 2 diabetes,
but the presence of these other chronic “physical” diseases
was said to be of little influence. Only one patient was pre-
scribed an AD mainly for restless legs syndrome, which is
in fact a well-known side effect of ADs.
Implications for practice
Many of these AD prescriptions, including those for
non-psychiatric conditions, seemed scientifically justi-
fied. We did not find “unexplained” prescriptions, but
this did not mean that all of them were fully appropriate.
Thus, these results indicate areas for improvement.
Firstly, the GPs should be aware of the influence of
their patients ‘context of life, such as family or work re-
lated problems, on their prescription behaviour. A bio
psycho social approach, patient’s centered, is therefore
relevant in PC settings: It helps to build the relationship
and to understand the patients’ perspective in cases of
stressful life events. These events seem to have too much
influence on the AD prescription decisions of GPs.
Secondly, at the opposite, patients with chronic dis-
eases did not seem to trigger AD prescriptions, even
though they are a well-known factor for depression,
sometimes leading to higher morbidity outcomes [29].
Do GPs pay enough attention of mood disturbances
amongst these patients?
Thirdly the important number of patients for whom
the prescription was not initiated by the GP himself
has to be underlined: We do not know how these pre-
scriptions are re-assessed. Their appropriateness should be
questioned.
Implications for a broader study
This pilot study also specifically assessed the feasibility of
a larger study. The aim will be to confirm these findings
with a representative GP population sample. We sought
to precisely present the rate of “prescriptions for non-
psychiatric conditions”. Based on the outcome of this pilotstudy (i.e. an 18% rate of AD prescriptions for non-
psychiatric conditions), with a 95% confidence interval, a
sample of 600 AD prescriptions will be required in order
to obtain a minimum of 120 non-psychiatric prescriptions.
With three prescriptions assessed for each GP, an intra-
cluster correlation coefficient of 0.01 must be taken into
account. The required sample of patient files and GPs will
be 612 and 204 respectively. As a result, the mean number
of patients eligible per week for the main study can
roughly be estimated at three per GP per week. Taking
into account Lasagna’s law for prevalence studies, we can
assume that two eligible patients per week is probably
more realistic [30].
Implication for further research
We observed that some GPs prescribed ADs four times
less frequently than others. Many hypotheses can be
made. Differences in consumption could be related to
differences between areas or countries [5]. Urbanization
could influence the prevalence of mood disorders [31]. Pa-
tient characteristics, physician characteristics, the health
care system, and interactions between these three compo-
nents, all influence AD prescription [32]. The medical cur-
riculum can influence the ability of the GPs to recognize
and treat mood disorders [33]. In a full study, the influ-
ence of the GPs’ practice location, their conviction regard-
ing the efficacy of ADs, the number of patients seen, and
the organization of the practice (solo or group practice)
on AD prescription rate should be explored. Two other
problems should be taken into account, i.e. a possible
memory bias and under-recording of AD prescriptions.
To ensure representativeness, the rate of AD prescriptions
during four weeks of inclusion will be compared with
the rate of annual AD prescription according to the
French social security system. One challenge will be to
understand differences in the rates of AD prescription
by individual GPs and to interpret their prescription
behaviour. This study, using a mixed-method design,
will provide the chance to set up an opportunistic sam-
ple to perform qualitative interviews among these GPs
in order to disclose their conception of care and their
style of practice that potentially influences their AD
prescriptions.
Strengths and weaknesses
This study assessed the influence of all patient character-
istics according to the GPs, but was not designed to as-
sess the reliability of their diagnosis with a standardized
questionnaire. Thus, the level of appropriateness of AD
prescription for depression and anxiety should be inter-
preted with caution. Psychiatric co morbidities are fre-
quently associated in depressed people. Personality disorders
could range for 25% of the patients treated with ADs. The
presence of these disorders seems to negatively impact
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closed prescription for several patients having “symp-
toms of depression” without all the items of the DSM
5 major depressive episode. Only a precise assessment
of the patient‘s symptoms and personality could have
provided an answer on fully appropriate or inappro-
priate AD prescriptions. Nevertheless this is a difficult
challenge and subject of debate among psychiatrists.
Medicalization of sadness in the context of our society
is also an important issue, as people complain but are
not being assessed as depressed by standardized instru-
ments. Horwitz pointed out the changing conception
of sadness and depression in our modern world [35].
For him, the limits of the concept of “depressive dis-
order” are vague. In the context of medicalization of
life problems, it is tempting for the GP to analyse com-
plaints only from a medical point of view. This could
lead them to treat only symptoms of anxiety or sadness
as a mental disorder.
Another possible bias could be different ways of practice
among the GP participants: It is likely that GPs mentoring
students are more prone to follow EBM guidelines. Such a
behaviour could lower the rate of overall AD prescription
and change the relative weight of the factors influencing
the AD prescription. Nevertheless, the figures on the rate
of prescription for non-psychiatric conditions were con-
sistent with the range of calculations made based on the
available literature. Collaboration of the GPs, availability of
the data, and comprehensibility of the questionnaire were
ensured, which is consistent with good internal and exter-
nal validities. This is a pilot study: All of these data have
allowed us to precisely design the protocol of a full study
that will be done in order to validate these preliminary re-
sults in a larger population.Conclusion
The mean rate of AD prescription by GPs was nearly
9%. Among these, nearly 20% were prescriptions for
non-psychiatric conditions. Non-psychiatric prescriptions
were mainly related to complex contextual situations and
multi-morbid patients. These preliminary results empha-
sise the influence of social and psychological factors in
the GP’s decision for this prescription. This pilot study
ensures the feasibility of our upcoming study that aims
to more precisely assess the reasons for and influences
on this prescription behaviour.
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